May 8, 2008
Metametrix Introduces the New Neopterin/Biopterin Profile
DULUTH, Ga., May 8 /PRNewswire/ -- Metametrix Clinical Laboratory ( http://www.metametrix.com/ ), a leader in nutritional and metabolic testing, announced the introduction of the urinary Neopterin/Biopterin Profile. This latest testing profile measures the oxidative products of tetrahydrobiopterin (BH4).
Neopterin and biopterin are by-products of the redox reactions involving tetrahydrobiopterin (BH4). Restricted BH4 availability has been suggested as an etiologic factor in neurological diseases such as Alzheimer's disease, Parkinson's disease, Autism Spectrum Disorders, depression, and DOPA-responsive dystonia; insulin resistance; cardiovascular disease, and inborn-errors of metabolism including phenylketonuria and hyperphenylalaninemia. Neopterin is also found elevated in infections; autoimmune diseases, such as rheumatoid arthritis, systemic lupus, and atopic asthma; malignant disease; psychiatric disorders; and sleep-disordered breathing. Low biopterin levels may reflect insufficient BH4 status.
Metametrix Clinical Laboratory has for the past 24 years specialized in producing innovative, Next Generation Technologies(SM) for measuring nutritional, metabolic, and toxic influences on health. Metametrix is a leader in providing quality, innovation, and education with integrative and functional testing services to healthcare professionals around the world.
For Information: http://www.metametrix.com/ Contact: [email protected] Phone: 800-221-4640
Metametrix Clinical Laboratory
CONTACT: Jennifer Gillen, Marketing Manager of Metametrix ClinicalLaboratory, +1-800-221-4640, [email protected]
Web site: http://www.metametrix.com/